explain this to me, page-2

In a sense you're flogging a dead horse on this one Primatron. I dare say many of the previous long term "burnt" holders have well and truly left this stock.
I still watch from the sidelines as one of those previous holders. As I've stated in past postings this company could have gone places in terms of delivering shareholder return if it had savy management. It still has the science to go places but perhaps just as likely the science will get sold for a song. Bioshares have stated it has possibily been thrown a late life line in terms of raising funds as a result of the FDA's very positive stance on cancer vaccine therapies. I note however Bioshares in their article recognised the need for a new and more experienced management team. They also indicated they expected the departure of caretaker CEO Eugene Kopp towards the end of the year.
I will continue to watch the space with interest.